Guotai CSI BIOMEDICINE ETF(512290) Rises 3.11%, with Latest Net Capital Inflow of RMB 54.0455 Million

NewTimeSpace (newtimespace.com) News, – As of 09:50 on August 4, 2026, Guotai Biopharmaceutical ETF (512290) rose 3.11%, with its latest price at RMB 1.03. Over a longer horizon, as of August 3, 2026, the ETF had accumulated a gain of 1.32% over the past 3 months.

In terms of liquidity, Guotai Biopharmaceutical ETF recorded a turnover rate of 2.97% during the session, with trading volume reaching RMB 110 million. Over a longer period, as of August 3, the ETF’s average daily turnover over the past month was RMB 210 million.

In terms of scale, the latest asset size of Guotai Biopharmaceutical ETF stood at RMB 3.578 billion. (Data source: Wind)

On capital inflows, the latest net capital inflow for Guotai Biopharmaceutical ETF was RMB 54.0455 million. Over a longer horizon, over the past 5 trading days, the total net inflow amounted to RMB 16.7347 million. (Data source: Wind)

Data shows that leveraged funds are continuing to position themselves. The latest margin buying amount for Guotai Biopharmaceutical ETF reached RMB 8.5063 million, with its latest margin balance standing at RMB 126 million. (Data source: Wind)

As of August 3, the net value of Guotai Biopharmaceutical ETF had risen 16.44% over the past 2 years. In terms of return capability, as of August 3, 2026, since its inception, the ETF achieved a highest single‑month return of 23.26%, a longest consecutive winning streak of 8 months with a cumulative gain of 109.28%, and an average monthly return of 6.38% during up months. As of August 3, 2026, the ETF’s 3‑month excess annualized return over its benchmark was 4.83%.

In terms of drawdown, as of August 3, 2026, the ETF’s half‑year drawdown relative to its benchmark was 0.13%. The recovery period after drawdown was 36 days.

On fees, Guotai Biopharmaceutical ETF charges a management fee of 0.50% and a custody fee of 0.10%.

On tracking accuracy, as of August 3, 2026, the ETF’s 3‑year tracking error was 0.036%.

Guotai Biopharmaceutical ETF closely tracks the CSI Biopharmaceutical Index. The index selects listed company securities that provide products and services such as cell therapy, gene sequencing, blood products, biotech drugs, vaccines, and in vitro diagnostics as index samples, reflecting the overall performance of listed companies in the biopharmaceutical industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.